Introduction
Ovarian cancer is the most lethal gynecological cancer, accounting for approximately 14 000 deaths in the United States each year. Owing to the lack of effective screening tools and inconspicuous early symptoms, most patients with ovarian cancer are diagnosed at advanced stages. Despite the advancements in surgical debulking and chemotherapy, most patients will ultimately manifest recurrence and ultimately succumb to this disease. Recently, gene therapy has become a promising new therapeutic option in the treatment of ovarian cancer, and is currently under intensive clinical investigation utilizing a variety of transgenes. [1] [2] In addition to selection of therapeutic genes, the choice of an effective gene delivery vector is crucial for the success of this strategy. Adenovirus type 5-based vector (Ad5) is mostly favored over other vector systems because of its high gene transfer efficacy and high titer production. However, recent studies have shown that expression of the primary Ad5 receptor, coxsackie-adenovirus receptor (CAR), is often low on malignant ovarian and other types of tumors, thus infection of tumor cells by Ad5 vectors is not efficient. [3] [4] [5] This is consistent with clinical observations and explains, at least in part, the relative resistance of ovarian carcinomas to Ad5 infection. Therefore, overcoming CAR deficiency is a key to the success of ovarian cancer gene therapy.
Several studies have shown that genetic incorporation of foreign targeting motifs into fiber, the Ad5 capsid protein that binds to CAR, can achieve CAR-independent gene delivery. [6] [7] [8] [9] [10] [11] [12] Two targeting motifs, RGD and polylysine (pK7), are particularly interesting because their receptors, integrin for RGD peptide and cell-surface proteins containing polyanion motifs such as heparan sulfate for the positively charged pK7 peptide, are widely expressed and such expression is often regulated by development, tumor metastasis, or other factors. [13] [14] [15] [16] [17] [18] Vectors containing either RGD (Ad5.RGD) or pK7 (Ad5.pK7), or both (Ad5.RGD.pK7) have been shown to infect a variety of cells with greatly enhanced infectivity. [7] [8] [9] [11] [12] 19 However, their utility in ovarian cancer has not been systemically explored. In this study, we evaluated these vectors and compared their gene delivery efficiency in ovarian carcinomas using cultured ovarian carcinoma cell lines, primary ovarian tumor cells, and ovarian cancer animal models. Our study provided valuable information for ovarian cancer gene therapy with regard to the utility of the infectivity-enhanced Ad5 vectors.
Results and discussion
As an initial evaluation for the gene delivery efficacy of the infectivity-enhanced vectors containing RGD, pK7, or both RGD and pK7, we tested their infectivity in various ovarian carcinoma-derived cell lines OV-4, Hey and SKOV3.ip1. Unmodified Ad5 vector (Ad5) was used as control. To eliminate potential effects resulted from different virus preparations, viruses used in this study were from the same virus lots. In these experiments, cells were infected with viruses equivalent to multiplicity of infections (MOIs, viral particles (VPs) per cell) of 1, 10, 100, and gene delivery efficacy was determined 24 h after infection using the reporter gene luciferase that was incorporated in the E1 region of each viral genome. We found that all of the modified vectors showed significantly enhanced infectivity, with Ad5.RGD.pK7 exhibiting the highest efficacy in all of the three cell lines that ranged from seven to 55-folds higher than the unmodified Ad5 vector ( Figure 1 ). In particular, Ad5.RGD showed the modest infectivity enhancement in SKO-V3.ip1 cells (B40% higher than unmodified Ad5), whereas Ad5.RGD.pK7 exhibited the most prominent enhancement in Hey cells (more than 50-folds higher than unmodified Ad5). This suggested Ad5.RGD.pK7 was more efficient in delivering transgenes into ovarian carcinoma cells cultured in vitro.
Since established cell lines may exhibit distinct properties from original ovarian carcinoma cells due to culturing in vitro, we employed primary cultures to more closely resemble ovarian tumor cell phenotypes in patients. In this regard, we first purified ovarian cancer cells from the ascites of ovarian cancer patients using CC49 antibody that recognizes a tumor cell surface marker, the pancarcinoma tumor-associated glycoprotein 72 (TAG-72). 20 Samples from four patients (patient #3, 8, 9, and 22) were used. Immunofluorescent staining of the purified cells with CC49 antibody confirmed that they were tumor cells (Figure 2a ). After the cells were cultured in suspension overnight to recover from trypsin treatment, they were infected with the viruses at MOI ¼ 100. The cells were then lysed and subjected to luciferase assay. As shown in Figure 2b , although samples from different patients exhibited differential responses to virus infections, Ad5.pK7 and Ad5.RGD.pK7 constantly appeared to be more effective than unmodified Ad5 (Po0.01). Ad5.RGD did not show significant improvement in the primaries tested in this study (P40.05) (Figure 2b ). In contrast, a previous study published by Kanerva et al 21 showed that Ad5.RGD exhibited significantly enhanced infectivity in the primary cells purified from two out of five ovarian cancer patients. These variable responses may result from different cell types of tumor origins in these patients, different stages of tumor progression, or simply from variations in the expression of cell surface proteins in individual patients.
Furthermore, we sought to test in vivo gene transfer efficacy of the modified Ad5 vectors using animal models. Two ovarian tumor models were employed for this purpose. In the first one, we established a tumor model by subcutaneous injection of ovarian carcinomaderived Hey cells into the athymic nude mice because Hey cells have been shown to form subcutaneous tumors easily and the vectors demonstrated highly improved infectivity in vitro. When the tumors developed to a size of B5 mm in diameter, 10 10 VPs were injected into each mouse by direct intratumor injections, and luciferase activity in the tumors was measured 3 days after viral injection. We found that, although all of the modified vectors exhibited higher gene delivery efficiency, only Ad5.RGD.pK7 showed statistically significant infectivity enhancement compared to unmodified Ad5 vectors (Po0.05) (Figure 3 ). Gene transfer in liver was very limited for all of the vectors after intratumor injection, in which tumor-to-liver ratios of luciferase activity in 100 mg tissue were more than 1000 (data not shown). These data suggested that Ad5.RGD.pK7 was efficient 5 cells/well the day before infection, and infected with viruses equivalent to MOI 1, 10, and 100. At 24 h after infection, the cells were lysed in reporter lysis buffer (RLB) (Promega), and 5 ml of each sample was used to measure the luciferase activity with a luciferase assay kit (Promega) and a luminometer (Berthold, Gaithersburg, MD, USA). The relative light units (RLU) data represent the luciferase activity in each sample. The numbers shown above the bars of MOI 10 infections represent the average fold differences from unmodified Ad5 at different MOIs. Except Ad5.RGD in SKOV3.ip1 cells (P40.05), all of the modified vectors showed significant infectivity enhancement compared to unmodified Ad5 vector in the three cell lines (Po0.001), as analyzed by Student's t-test.
Infectivity
Ovarian cancer usually remains confined to the abdominal cavity throughout its course, thus gene delivery via intraperitoneal (i.p.) route may offer a feasible and effective means to achieve high virus load in the close tumor environment. Therefore, we next employed a second ovarian tumor model -an i.p. tumor model. In this model, ovarian carcinoma-derived SKO-V3.ip1 cells, which have been shown to form tumors in mouse peritoneum nicely, were injected into the peritoneal cavity of severe combined immunodeficient (SCID) mice to develop tumors. Two weeks later, 10 10 VPs were injected into each mouse by i.p. injections. The infectivity of each virus in the tumors was examined after the mice were killed and tumors (B0.1 g/mouse) were obtained. Interestingly, in this model, Ad5.pK7 showed the highest gene delivery efficiency in the tumors (about nine-folds higher than Ad5) (Figure 4a ). Ad5.RGD.pK7 and Ad5.RGD appeared to infect the tumors more effectively than unmodified Ad5 vector (about 3.5-and two-folds higher, respectively), but the differences were not statistically significant (P40.05) (Figure 4a ). Further, we examined whether the gene transfer in other organs were altered, and found the major luciferase activity was located in the liver. By comparing the tumor-to-liver ratios of luciferase activity in each 100 mg tissue, we found that Ad5.RGD and Ad5.RGD.pK7 had similar ratios (2.6 and 3.22, respectively) to unmodified Ad5 (2.5), whereas Ad5.pK7 had higher tumor-to-liver ratio Figure 2 Infectivity of different Ad5 vectors in primary ovarian cancer cells. Primary ovarian cancer cells were purified essentially as described by Barker et al. 20 In brief, the ascites were obtained from each ovarian cancer patient at the time of initial surgery by physicians in the Division of Gynecological Oncology at the University of Alabama at Birmingham (Birmingham, AL, USA), and the noncellular portion was removed by centrifugation. The erythrocytes were then lysed in a 5:1 mixture of phosphate-buffered saline (PBS) and ACK lysis buffer (0.15 M NH 4 Cl, 1.0 mM KHCO 3 , 0.1 mM EDTA). The remaining cells were resuspended in 10 ml of RPMI-1640 freezing medium. To purify ovarian cancer cells from the cells, after washing the cells with PBS containing 0.1% bovine serum albumin (PBS/BSA), a monoclonal antibody CC49 (a generous gift from J Schlom, National Institutes of Health, Bethesda, MD, USA) that was raised against tumor cell surface marker TAG-72 antigen was used to bind the ovarian tumor cells, followed by incubation with the secondary antibody against mouse IgG that was coupled to magnetic Dynabeads (Dynal AS, Oslo, Norway). The cells were then washed with PBS/ BSA using Dynal Magnetic Particle Concentrator (MPC; Dynal AS, Oslo, Norway). The cells bound to the magnetic Dynabeads were then released by trypsin treatment, and cultured in RPMI complete media at 371C with 5% CO 2 . (a) Image of the purified primary ovarian cancer cells. Cells purified from the ascites of four ovarian cancer patients (P3, P8, P9, and P22) were subjected to phase-contrast imaging and immunofluorescent imaging after staining with CC49 antibody and Texas Red-conjugated secondary antibody. The results suggested the purified cells were tumor cells. (b) Gene transfer efficacy of Ad5, Ad5.RGD, Ad5.pK7, and Ad5.RGD.pK7 in the purified primary ovarian cancer cells. The primary cells were plated in 96-well ultra-low attachment plates (Corning Incorporated, NY, USA) with a density of 2 Â 10 4 cells/well in 50 ml RPMI complete media right after purification. Viruses equivalent to MOI 100 were used to infect cells in each well, and continued incubation for 6 h at 371C, 5% CO 2 before addition of RPMI complete media. After 24 h, the infected cells were collected into microcentrifuge tubes by pipetting and centrifugation. The cell pellets were then washed with PBS, and subjected to luciferase assay as described in Figure 1 . The asterisks (*) mark the data that are significantly different from unmodified Ad5 vector (Po0.01, Student's t-test). The numbers on top of each bar show the fold differences compared to unmodified Ad5 vector.
Infectivity-enhanced adenoviruses for ovarian cancer H Wu et al (6.05) (Figure 4b ). Together, these data indicated that Ad5.pK7 was the most efficient vector for gene delivery in the i.p. ovarian tumor model. In this study, we evaluated the potential utility of infectivity-enhanced Ad5 vectors containing RGD, pK7, or both RGD and pK7 in ovarian cancer gene therapy. Our data showed that these vectors worked efficiently in delivering transgenes into ovarian carcinoma cell lines and primary cells. On the other hand, in in vivo models, infectivity-enhancement achieved by these vectors was not as impressive as in in vitro assays, and the two tumor models exhibited differential results -Ad5.RGD.pK7 showed significant improvement for subcutaneous tumors developed from Hey cells, but for i.p. tumors derived from SKOV3.ip1 cells, Ad5.pK7 appeared to be most efficient.
These data clearly suggest that in vivo factors limit the infection of Ad5 vectors, consistent with other in vivo studies. 8, 12, 22 In a recent study, Koizumi et al, 12 who independently constructed the doubly modified vector Ad5.RGD.pK7 and the singly modified vectors Ad5.RGD and Ad5.pK7, have found that Ad5.RGD.pK7 has the highest efficacy in delivery transgenes into cultured mouse melanoma B16 cells compared to Ad5, Ad5.RGD, and Ad5.pK7. However, the efficacy is much lower in B16 tumors inoculated in mouse abdomens after intratumor injection of the vectors. Interestingly, Ad5.RGD appears to be the most efficient vector for delivering genes into B16 tumors in vivo. Another study involving Ad5.RGD and Ad5.pK7 has suggested that Ad5.pK7 is more efficient than Ad5.RGD in delivering transgenes into several glioma tumor models. 22 These data, together with our study, indicate that infectivity-enhanced vectors may exhibit distinct utilities that are dependent upon the tumor origin, route of vector administration, and the tumor target context. Why the vectors behave so differently in vivo from in vitro is not clear. One of the reasons could be that the nontumor cells in the tumors create barriers relevant to tumor penetration. Another factor affecting viral infection could be the extracellular matrix, as speculated by other investigators. 12, 23 For example, pK7 peptide can interact with heparan sulfate moieties in the extracellular matrix, thus pK7-containing vectors may be sequestered, resulting in less infection of the tumor cells. Furthermore, the innate host immunity may also play a role in limiting viral infection even for the locally administered vectors due to the blood supply in the tumors. Extra motifs often represent extra targets for the immune system, thus compromise the degree of infectivity enhancement for the vectors.
The important value of this study is that we systemically evaluated the infectivity-enhanced vectors for their utility in ovarian cancer gene therapy. Several tropism-modified vectors have been tested in the context of ovarian cancer gene therapy previously, including Ad5.RGD and an Ad5 vector in which the CAR-binding knob domain of Ad5 is replaced with Ad3 knob (Ad5/ 3). [24] [25] [26] Both of the vectors have been shown to improve gene transfer and therapeutic efficacy in ovarian cancer 10 VPs of each virus diluted in 30 ml of PBS were injected directly into the tumors (intratumor injection). Five mice were used for each virus. At 3 days following the virus injections, the mice were killed, and the tumors were collected for luciferase assay as described. 11 The RLU data represent the average readings for 2 ml of each sample lysed in 200 ml lysis buffer per 100 mg of tumor tissue. Figure 4 Gene transfer efficacy of the Ad5 vectors in intraperitoneal ovarian cancer mouse model. To establish intraperitoneal (i.p.) mouse model for ovarian carcinoma, 10 7 SKOV3.ip1 cells were injected into the peritoneal cavity of each SCID mouse (Charles River), and the tumors were allowed to develop for 2 weeks. 10 10 VPs of different viruses were then injected into each mouse via i.p. injection, and five mice were used for each virus type. At 3 days following the virus injections, the mice were killed, and the tumors and livers were collected for luciferase assay as described in Infectivity-enhanced adenoviruses for ovarian cancer H Wu et al gene therapy. However, their efficacy has never been compared to that of other infectivity-enhanced vectors. By comparing the gene transfer efficacy of Ad5.RGD, Ad5.RGD.pK7, and Ad5.pK7, we found that Ad5.RGD.pK7 and Ad5.pK7 were more efficient than Ad5.RGD both in vitro and in vivo for ovarian cancer gene therapy. This suggests that Ad5.RGD.pK7 and Ad5.pK7 are very useful vectors for Ad5-based ovarian cancer gene therapy, and the choice of the vectors may depend on the types of tumor and the route of administration.
